These new findings suggest that variability in factor VIII (FVIII) half-life in patients, though impacted by all 3 factors, is largely attributed to variability in the clearance of endogenous von ...
The phase 3 GENEr8-1 study demonstrated that valoctocogene roxaparvovec, an AAV5-vectored gene therapy, effectively enabled endogenous FVIII production in adults with severe hemophilia A without ...
This page lists all known medications that could potentially lead to 'Factor VIII deficiency' as a side effect. It's important to note that mild side effects are quite common with medications. The ...
Various hematopoietic cell lines were transduced with pRRL-PPT-CMV-FVIII-W-SIN at a multiplicity of infection (MOI) of 10. After 6 days, normalized transduction rates were determined by real-time PCR ...
Figure 1: Hydrolysis of 125 I-labeled FVIII by affinity-purified IgG antibodies against FVIII of hemophilia A patients. We characterized the cleavage sites in the FVIII molecule by amino-acid ...
Altuviiio temporarily replaces the missing coagulation factor VIII needed for effective hemostasis. The Food and Drug Administration (FDA) has approved Altuviiio ™ (antihemophilic factor [recombinant] ...
Factor VIII inhibitors are IgG alloantibodies that arise during replacement therapy in 25 to 50 percent of patients with severe hemophilia A. The hydrolysis of factor VIII by anti–factor VIII ...
An open-label, phase 1 trial was conducted in six patients with severe hemophilia A. Dermal fibroblasts obtained from each patient by skin biopsy were grown in culture and transfected with a plasmid ...
Takeda is seeing some positive signals from its $3.6 billion deal with Poseida Therapeutics with promising preclinical data on the companies’ hemophilia A therapy P-FVIII-101. In an oral presentation ...
People with severe hemophilia A are at risk for prolonged bleeding events that can cause serious complications. To prevent these bleeding events, most people with this condition get injections of a ...
LONDON--(BUSINESS WIRE)--According to the latest market study released by Technavio, the global factor VIII deficiency treatment market is projected to grow to USD 11 billion, at a CAGR of close to 6% ...
The European Medicines Agency (EMA) this week recommended granting a marketing authorization for Altuvoct (efanesoctocog alfa) for the treatment and prophylaxis of bleeding in patients with hemophilia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback